Kleiner Perkins Caufield & Byers will invest in iZumi Bio, a biotech firm working on reprogramming adult cells to regain the properties of embryonic stem cells. IZumi announced Monday that it will collaborate with the J. David Gladstone Institutes in San Francisco to focus on research involving "induced pluripotent stem cells."

Related Summaries